Interpace Biosciences Reports 26% Q4 Revenue Drop Amid PancraGEN Exit, Core Thyroid Business Grows
summarizeSummary
Interpace Biosciences reported a 26% year-over-year decline in Q4 revenue to $9.22 million, primarily attributed to the discontinuation of its PancraGEN product. Despite the overall revenue drop, the company's core thyroid diagnostics business demonstrated strength, with thyroid test volume increasing 11% and thyroid revenue rising 14% year-over-year. Additionally, Q4 net income from continuing operations was significantly boosted to $22.66 million by a one-time, non-cash tax-related accounting adjustment. While the revenue decline is material, the growth in the core business and the positive outlook for 2026 thyroid revenue growth (approximately 16%) provide a more balanced picture. Traders will be watching for continued execution on scaling the thyroid segment and the impact of the PancraGEN discontinuation on future quarters.
At the time of this announcement, IDXG was trading at $1.66 on OTC in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $0.44 to $1.91. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.